Twist Bioscience
TWSTTwist Bioscience leverages its proprietary silicon-based DNA synthesis platform to manufacture high-quality, precise synthetic DNA at scale, enabling innovation across diverse fields. The company has expanded from core gene synthesis into high-growth markets like next-generation sequencing (NGS), antibody discovery, and synthetic biology tools. As a publicly traded company, Twist aims to be the foundational platform for the bioeconomy, supporting customers in accelerating research and development timelines.
TWST · Stock Price
Historical price data
AI Company Overview
Twist Bioscience leverages its proprietary silicon-based DNA synthesis platform to manufacture high-quality, precise synthetic DNA at scale, enabling innovation across diverse fields. The company has expanded from core gene synthesis into high-growth markets like next-generation sequencing (NGS), antibody discovery, and synthetic biology tools. As a publicly traded company, Twist aims to be the foundational platform for the bioeconomy, supporting customers in accelerating research and development timelines.
Technology Platform
Proprietary silicon-based DNA synthesis platform that enables high-throughput, precise, and cost-effective manufacturing of synthetic DNA, serving as the foundation for genes, oligo pools, NGS solutions, and synthetic biology tools.
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Human mAb 216 + Vincristine | Leukemia, Lymphocytic, Acute | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Twist competes with established players like IDT and GenScript in gene synthesis, Agilent and Roche in NGS capture, and specialized CROs in antibody discovery. Its core differentiation is its cost-effective, high-throughput silicon-based DNA synthesis platform, which provides scalability and quality advantages that are difficult for competitors to replicate.